-
- Comment in:
-
J Clin Invest. 1998 Apr 1;101(7):1293-5.
Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy.
Niehues R,
Hasilik M,
Alton G,
Körner C,
Schiebe-Sukumar M,
Koch HG,
Zimmer KP,
Wu R,
Harms E,
Reiter K,
von Figura K,
Freeze HH,
Harms HK,
Marquardt T.
Klinik und Poliklinik für Kinderheilkunde, 48149 Münster, Germany.
Phosphomannose isomerase (PMI) deficiency is the cause of a new type of carbohydrate-deficient glycoprotein syndrome (CDGS). The disorder is caused by mutations in the PMI1 gene. The clinical phenotype is characterized by protein-losing enteropathy, while neurological manifestations prevailing in other types of CDGS are absent. Using standard diagnostic procedures, the disorder is indistinguishable from CDGS type Ia (phosphomannomutase deficiency). Daily oral mannose administration is a successful therapy for this new type of CDG syndrome classified as CDGS type Ib.
PMID: 9525984 [PubMed - indexed for MEDLINE]
PMCID: PMC508719
-
Cited by 19 PubMed Central articles
-
Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function.
Bode L, Salvestrini C, Park PW, Li JP, Esko JD, Yamaguchi Y, Murch S, Freeze HH.
J Clin Invest. 2008 Jan; 118(1):229-38.
[J Clin Invest. 2008]
-
Translation attenuation by PERK balances ER glycoprotein synthesis with lipid-linked oligosaccharide flux.
Shang J, Gao N, Kaufman RJ, Ron D, Harding HP, Lehrman MA.
J Cell Biol. 2007 Feb 26; 176(5):605-16.
[J Cell Biol. 2007]
-
Analysis of glycosylation in CDG-Ia fibroblasts by fluorophore-assisted carbohydrate electrophoresis: implications for extracellular glucose and intracellular mannose 6-phosphate.
Gao N, Shang J, Lehrman MA.
J Biol Chem. 2005 May 6; 280(18):17901-9. Epub 2005 Feb 11.
[J Biol Chem. 2005]
- » See all...